suriclone

recognizes receptors labeled by benzodiazepines

Also Known As:

(8-(7-chloro(1,8)naphthyridin-2-yl)-7-oxo-2,5-dithia-8-azabicyclo(4.3.0)non-10-en-9-yl) 4-methylpiperazine-1-carboxylate; 6-(7-chloro-1,8-naphthyridin-2-yl)-2,3,6,7-tetrahydro-7-oxo-5H-(1,4)dithiino(2,3-c)pyrrol-5-yl-4-methylpiperazine-1-carboxylate; RP 31264; RP-3124; RP-31264

Networked: 8 relevant articles (0 outcomes, 3 trials/studies)

Bio-Agent Context: Research Results

Related Diseases

1.	Anxiety Disorders (Anxiety Disorder) 01/01/1987 - "Suriclone for generalized anxiety disorder: an escalating multiple-dose, safety, tolerance, and efficacy study." 01/01/1991 - "Controlled comparison of the efficacy and safety of four doses of suriclone, diazepam, and placebo in generalized anxiety disorder." 11/01/1989 - "A comparative study of suriclone, lorazepam and placebo in anxiety disorder." 11/01/1989 - "In a four-week double-blind randomized trial preceded by a one-week single-blind placebo treatment, the efficacy and the side-effects of suriclone (1.50-2.25 mg/d) (n = 24), lorazepam (5.0-7.5 mg/d) (n = 19) and placebo (n = 21) were compared in 64 outpatients with a DSM-III diagnosis of generalized anxiety disorder (n = 56) or panic disorder (n = 8). " 01/01/1983 - "Suriclone, a new psychotherapeutic agent chemically unrelated to benzodiazepines or phenothiazines was assessed in a single-blind dose-ranging study to determine its efficacy and safety in out-patients with generalized anxiety disorder. "
2.	Panic Disorder (Panic Attack) 11/01/1989 - "In a four-week double-blind randomized trial preceded by a one-week single-blind placebo treatment, the efficacy and the side-effects of suriclone (1.50-2.25 mg/d) (n = 24), lorazepam (5.0-7.5 mg/d) (n = 19) and placebo (n = 21) were compared in 64 outpatients with a DSM-III diagnosis of generalized anxiety disorder (n = 56) or panic disorder (n = 8). "
3.	Mobility Limitation (Difficulty Walking) 06/01/1988 - "Suriclone 0.8 mg caused nausea (p = 0.02), clumsiness (p = 0.02), and loss of balance (p = 0.01) more frequently than diazepam 10 mg. Suriclone 0.8 mg produced symptoms and signs qualitatively and quantitatively different from diazepam 10 mg, such as vomiting, unusual ocular movement effects, and difficulty walking. "
4.	Ganglion Cysts (Ganglion) 12/01/1987 - "In anesthetized dogs, suriclone 0.5 mg/kg i.v., did not affect the responses to vagal stimulation or to pre- and postganglionic stimulation of cardiac ganglion. "
5.	Vomiting 06/01/1988 - "Suriclone 0.8 mg caused nausea (p = 0.02), clumsiness (p = 0.02), and loss of balance (p = 0.01) more frequently than diazepam 10 mg. Suriclone 0.8 mg produced symptoms and signs qualitatively and quantitatively different from diazepam 10 mg, such as vomiting, unusual ocular movement effects, and difficulty walking. "

Related Drugs and Biologics

1.	Benzodiazepines
2.	Phenothiazines
3.	Lorazepam (Ativan)
4.	Diazepam (Valium)
5.	Anti-Anxiety Agents (Anxiolytics)
6.	GABA-A Receptors (GABA(A) Receptor)
7.	Flumazenil (Romazicon)
8.	RP 59037
9.	ZK 93426
10.	norharman